IMNN
ImunonยทNASDAQ
--
--(--)
--
--(--)
IMNN Profile
Imunon, Inc.
A clinical-stage drug development company that develops immunotherapies and other anti-cancer nucleic acid-based therapies to treat cancer
997 Lenox Drive
, Suite 100
, Lawrenceville
, NJ 08648
--
Imunon, Inc., founded in 1982, is a Delaware corporation. Celsion is a fully integrated oncology drug development company dedicated to the development of innovative cancer treatments, including chemotherapy directing, immunotherapy and RNA- or DNA-based therapeutic combinations. The company's lead program is ThermoDox, a patented heat-activated liposomal encapsulation of doxorubicin, which is currently in Phase III clinical trials for the treatment of primary liver cancer (OPTIMA study) and Phase II clinical trials for the recurrence of chest wall breast cancer (DIGNITY study). Its pipeline also includes GEN-1 (formerly EGEN-001), DNA-based immunotherapy for ovarian cancer and local treatment for brain cancer. The company has three platform technologies for therapeutic development for those hard-to-treat cancers, new nucleic acid-based immunotherapies and other anticancer DNA or RNA therapies, including TheraPlas and TheraSilence. Beginning in the first half of 2014, the product ThermoDox is undergoing a Phase III clinical trial for primary liver cancer (OPTIMA study) and a Phase II clinical trial for recurrent chest wall breast cancer (DIGNITY study).
